» Articles » PMID: 38838226

Incidence and Outcomes of Cytomegalovirus Reactivation After Chimeric Antigen Receptor T-cell Therapy

Abstract

Cytomegalovirus (CMV) reactivation is a major complication among seropositive allogeneic hematopoietic cell transplantation recipients; however, data on CMV reactivation after chimeric antigen receptor (CAR) T-cell therapy are limited. We report the incidence and outcomes of 95 adult CMV-seropositive patients who received CAR T-cell therapy between February 2018 and February 2023. CMV outcomes were CMV reactivation (any viremia) and clinically significant CMV infection (cs-CMV). Thirty-one patients (33%) had evidence of CMV reactivation (any viremia), and 10 patients (11%) had cs-CMV. The median time from CAR T-cell infusion to CMV reactivation was 19 days (interquartile range [IQR], 9-31). The cumulative incidence of CMV (any viremia) was significantly higher among patients with grade 3 to 4 cytokine release syndrome (67 vs 28%; P = .01), and those who received corticosteroids (39 vs 21%; P = .03), anakinra (56 vs 28%; P = .02), or ≥2 immunosuppressants (41 vs 21%; P = .02). Receipt of corticosteroids (18 vs 0%; P = .004), tocilizumab (14 vs 0%; P = .04), anakinra (33 vs 7%; P = .008), and ≥2 immunosuppressants (20 vs 0%; P = .001) were all associated with cs-CMV. Receiving ≥2 immunosuppressants was associated with a twofold increase in CMV reactivation in multivariate analyses (adjusted odds ratio [aOR], 2.27; 95% confidence interval, 1.1-4.8; P = .03). Overall, the 1-year mortality was significantly higher in those with CMV reactivation (57% vs 23%; P = .001). Immunosuppression, particularly with corticosteroids, for the management of CAR T-cell toxicities, is a major risk factor for CMV reactivation.

Citing Articles

[Cytomegalovirus Encephalitis Presenting With Palpitations as the Initial Symptom After Hematopoietic Stem Cell Transplantation to Treat Acute Lymphoblastic Leukemia in a Child: A Case Report].

Chen Y, Zhang X, Xiao L, Qiao L, He G Sichuan Da Xue Xue Bao Yi Xue Ban. 2025; 55(6):1593-1596.

PMID: 39990830 PMC: 11839375. DOI: 10.12182/20241160110.


Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review.

Sassine J, Siegrist E, Chemaly R Viruses. 2025; 17(1).

PMID: 39861922 PMC: 11768728. DOI: 10.3390/v17010133.

References
1.
Chen G, Herr M, Nowak J, Ho C, Almyroudis N, Attwood K . Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica. 2022; 108(2):615-620. PMC: 9890024. DOI: 10.3324/haematol.2022.281719. View

2.
Camargo J, Kimble E, Rosa R, Shimose L, Bueno M, Jeyakumar N . Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2017; 24(4):806-814. DOI: 10.1016/j.bbmt.2017.11.038. View

3.
de la Asuncion C, Hernani R, Albert E, Gomez M, Gimenez E, Benzaquen A . Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: should it be systematically monitored?. Clin Microbiol Infect. 2023; 29(8):1093-1095. DOI: 10.1016/j.cmi.2023.05.010. View

4.
Rendo M, Joseph J, Phan L, DeStefano C . CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges. Blood Lymphat Cancer. 2022; 12:119-136. PMC: 9439649. DOI: 10.2147/BLCTT.S327016. View

6.
Marty F, Ljungman P, Chemaly R, Maertens J, Dadwal S, Duarte R . Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017; 377(25):2433-2444. DOI: 10.1056/NEJMoa1706640. View